13 research outputs found
Bioengineering and biomechanical approaches for pancreatic cancer
Pancreatic cancer is the fourth-leading cause of cancer related mortality and is predicted to be the second leading cause of cancer death by 2030. A hallmark feature of pancreatic ductal adenocarcinoma (PDAC) is dense fibrotic stroma surrounding the tumor, composed of extracellular matrix (ECM) and cells such as myofibroblasts. The properties of this stroma and functional contribution to carcinogenesis and disease progression has been the subject of intense focus in the past decade; yet, the role of mechanobiology in modulating the phenotype of immune cells in the tumor microenvironment remains to be elucidated. Although a lack of understanding PDAC etiology and progression limits effective treatments that can be deployed by clinicians, current methods of diagnosing PDAC likely are insufficient even if such treatments exist, especially if there is a narrow early window for drug efficacy. Recently, however, extracellular vesicles have emerged as powerful circulating blood biomarkers, thus paving the way for a new era of non-invasive cancer diagnostics. However, currently the process of extracellular vesicle isolation and detection is not only highly inefficient, but also technically challenging.
This thesis describes bioengineering tools and biomechanical investigations of pancreatic cancer. In Chapter 2, the biomechanical phenotype of macrophages is studied in context of a stromal modulation agent, the chemotherapeutic drug tamoxifen. Tamoxifen was found to regulate macrophage focal adhesion dynamics, cytoskeletal activity, migratory behavior, and expression of TLR4. In Chapter 3, a novel microfluidic device was modeled and built to determine cell adhesion strength with potential applications to investigate regulation of focal adhesion structure by candidate drugs. Chapter 4 describes the development of methods and devices for isolation and detection of extracellular vesicles using acoustophoresis and a graphene field effect transistor, respectively. Such tools and perspectives could serve to detect PDAC earlier as well as identify and test new therapies.Open Acces
Tamoxifen mechanically reprograms the tumor microenvironment via HIFâ1A and reduces cancer cell survival
The tumor microenvironment is fundamental to cancer progression, and the influence of its mechanical properties is increasingly being appreciated. Tamoxifen has been used for many years to treat estrogenâpositive breast cancer. Here we report that tamoxifen regulates the level and activity of collagen crossâlinking and degradative enzymes, and hence the organization of the extracellular matrix, via a mechanism involving both the G proteinâcoupled estrogen receptor (GPER) and hypoxiaâinducible factorâ1 alpha (HIFâ1A). We show that tamoxifen reduces HIFâ1A levels by suppressing myosinâdependent contractility and matrix stiffness mechanosensing. Tamoxifen also downregulates hypoxiaâregulated genes and increases vascularization in PDAC tissues. Our findings implicate the GPER/HIFâ1A axis as a master regulator of periâtumoral stromal remodeling and the fibrovascular tumor microenvironment and offer a paradigm shift for tamoxifen from a wellâestablished drug in breast cancer hormonal therapy to an alternative candidate for stromal targeting strategies in PDAC and possibly other cancers.See also: E Cortes et al (January 2019) andM Pein & T Oskarsson (January 2019)EMBO Reports (2019) 20: e46557Peer reviewe
Navigating the Collagen Jungle: The Biomedical Potential of Fiber Organization in Cancer
Recent research has highlighted the importance of key tumor microenvironment features, notably the collagen-rich extracellular matrix (ECM) in characterizing tumor invasion and progression. This led to great interest from both basic researchers and clinicians, including pathologists, to include collagen fiber evaluation as part of the investigation of cancer development and progression. Fibrillar collagen is the most abundant in the normal extracellular matrix, and was revealed to be upregulated in many cancers. Recent studies suggested an emerging theme across multiple cancer types in which specific collagen fiber organization patterns differ between benign and malignant tissue and also appear to be associated with disease stage, prognosis, treatment response, and other clinical features. There is great potential for developing image-based collagen fiber biomarkers for clinical applications, but its adoption in standard clinical practice is dependent on further translational and clinical evaluations. Here, we offer a comprehensive review of the current literature of fibrillar collagen structure and organization as a candidate cancer biomarker, and new perspectives on the challenges and next steps for researchers and clinicians seeking to exploit this information in biomedical research and clinical workflows
Navigating the Collagen Jungle: The Biomedical Potential of Fiber Organization in Cancer
Recent research has highlighted the importance of key tumor microenvironment features, notably the collagen-rich extracellular matrix (ECM) in characterizing tumor invasion and progression. This led to great interest from both basic researchers and clinicians, including pathologists, to include collagen fiber evaluation as part of the investigation of cancer development and progression. Fibrillar collagen is the most abundant in the normal extracellular matrix, and was revealed to be upregulated in many cancers. Recent studies suggested an emerging theme across multiple cancer types in which specific collagen fiber organization patterns differ between benign and malignant tissue and also appear to be associated with disease stage, prognosis, treatment response, and other clinical features. There is great potential for developing image-based collagen fiber biomarkers for clinical applications, but its adoption in standard clinical practice is dependent on further translational and clinical evaluations. Here, we offer a comprehensive review of the current literature of fibrillar collagen structure and organization as a candidate cancer biomarker, and new perspectives on the challenges and next steps for researchers and clinicians seeking to exploit this information in biomedical research and clinical workflows
Recommended from our members
Liver epithelial focal adhesion kinase modulates fibrogenesis and hedgehog signaling
Focal adhesion kinase (FAK) is an important mediator of extracellular matrix-integrin mechano-signal transduction that regulates cell motility, survival, and proliferation. As such, FAK is being investigated as a potential therapeutic target for malignant and fibrotic diseases, and numerous clinical trials of FAK inhibitors are underway. The function of FAK in nonmalignant, nonmotile epithelial cells is not well understood. We previously showed that hepatocytes demonstrated activated FAK near stiff collagen tracts in fibrotic livers. In this study, we examined the role of liver epithelial FAK by inducing fibrotic liver disease in mice with liver epithelial FAK deficiency. We found that mice that lacked FAK in liver epithelial cells developed more severe liver injury and worse fibrosis as compared with controls. Increased fibrosis in liver epithelial FAK-deficient mice was linked to the activation of several profibrotic pathways, including the hedgehog/smoothened pathway. FAK-deficient hepatocytes produced increased Indian hedgehog in a manner dependent on matrix stiffness. Furthermore, expression of the hedgehog receptor, smoothened, was increased in macrophages and biliary cells of hepatocyte-specific FAK-deficient fibrotic livers. These results indicate that liver epithelial FAK has important regulatory roles in the response to liver injury and progression of fibrosis
Liver epithelial focal adhesion kinase modulates fibrogenesis and hedgehog signaling
Focal adhesion kinase (FAK) is an important mediator of extracellular matrixâintegrin mechano-signal transduction that regulates cell motility, survival, and proliferation. As such, FAK is being investigated as a potential therapeutic target for malignant and fibrotic diseases, and numerous clinical trials of FAK inhibitors are underway. The function of FAK in nonmalignant, nonmotile epithelial cells is not well understood. We previously showed that hepatocytes demonstrated activated FAK near stiff collagen tracts in fibrotic livers. In this study, we examined the role of liver epithelial FAK by inducing fibrotic liver disease in mice with liver epithelial FAK deficiency. We found that mice that lacked FAK in liver epithelial cells developed more severe liver injury and worse fibrosis as compared with controls. Increased fibrosis in liver epithelial FAK-deficient mice was linked to the activation of several profibrotic pathways, including the hedgehog/smoothened pathway. FAK-deficient hepatocytes produced increased Indian hedgehog in a manner dependent on matrix stiffness. Furthermore, expression of the hedgehog receptor, smoothened, was increased in macrophages and biliary cells of hepatocyte-specific FAK-deficient fibrotic livers. These results indicate that liver epithelial FAK has important regulatory roles in the response to liver injury and progression of fibrosis